{"id":187184,"date":"2026-08-06T11:38:39","date_gmt":"2026-08-06T06:08:39","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=187184"},"modified":"2026-08-06T11:38:41","modified_gmt":"2026-08-06T06:08:41","slug":"cipla-vs-lupin-comparison-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/","title":{"rendered":"Cipla vs Lupin: Which Stock Should You Track"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Cipla MCap Rs 1,17,138 Cr, PE 34.91x, ROE 11.27%, D\/E 0.02. Lupin MCap Rs 1,08,638 Cr, PE 20.29x, ROE 23.76%, D\/E 0.29.<\/em><\/p>\n<p>Cipla vs Lupin is a comparison mid-to-large pharma investors look up when evaluating two of India&#8217;s leading pharmaceutical companies with strong US generic businesses and branded Indian formulations. Cipla is a Mumbai-based company known for its respiratory inhalers, anti-infective drugs and US generic filings, while Lupin is a Mumbai-based pharma company with strong cardiology and CNS branded prescriptions in India, a significant US generics business and a growing dermatology pipeline.<\/p>\n<p>This Cipla vs Lupin article covers reach and market position, key products, latest declared results and stock valuation. The Cipla vs Lupin data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Cipla_vs_Lupin_Reach_and_Market_Position\" title=\"Cipla vs Lupin: Reach and Market Position\">Cipla vs Lupin: Reach and Market Position<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Cipla_vs_Lupin_Key_Products_and_Business_Mix\" title=\"Cipla vs Lupin: Key Products and Business Mix\">Cipla vs Lupin: Key Products and Business Mix<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Cipla_vs_Lupin_Latest_Results\" title=\"Cipla vs Lupin: Latest Results\">Cipla vs Lupin: Latest Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Cipla_vs_Lupin_Stock_and_Valuation\" title=\"Cipla vs Lupin: Stock and Valuation\">Cipla vs Lupin: Stock and Valuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Cipla_vs_Lupin_Quick_Comparison_Table\" title=\"Cipla vs Lupin: Quick Comparison Table\">Cipla vs Lupin: Quick Comparison Table<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#What_is_the_main_difference_between_Cipla_and_Lupin\" title=\"What is the main difference between Cipla and Lupin?\">What is the main difference between Cipla and Lupin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Which_company_has_the_higher_ROE\" title=\"Which company has the higher ROE?\">Which company has the higher ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Which_stock_trades_at_a_lower_PE\" title=\"Which stock trades at a lower P\/E?\">Which stock trades at a lower P\/E?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#What_is_Ciplas_inhaler_strategy\" title=\"What is Cipla&#8217;s inhaler strategy?\">What is Cipla&#8217;s inhaler strategy?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Why_does_Cipla_trade_at_a_premium_to_Lupin\" title=\"Why does Cipla trade at a premium to Lupin?\">Why does Cipla trade at a premium to Lupin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#What_risks_apply_to_pharma_companies\" title=\"What risks apply to pharma companies?\">What risks apply to pharma companies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-comparison-2\/#Should_I_invest_in_Cipla_or_Lupin\" title=\"Should I invest in Cipla or Lupin?\">Should I invest in Cipla or Lupin?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Reach_and_Market_Position\"><\/span><strong>Cipla vs Lupin: Reach and Market Position<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>On the Cipla side of the Cipla vs Lupin comparison, Cipla sells respiratory drugs, anti-infectives, oncology and hospital critical care products in India and generics in the US, South Africa and Europe. Market capitalisation is Rs 1,17,138 Cr.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=cipla-vs-lupin\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<p>On the Lupin side of the Cipla vs Lupin comparison, Lupin sells branded cardiology, CNS, anti-infective and diabetes prescriptions in India and generics in the US, Europe and rest of world. Market capitalisation is Rs 1,08,638 Cr.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Key_Products_and_Business_Mix\"><\/span><strong>Cipla vs Lupin: Key Products and Business Mix<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In the Cipla vs Lupin product comparison, Cipla offers: Cipla makes inhalers (Seroflo, Asthalin), anti-infectives, oncology drugs and US generics including inhaler biosimilars. P\/E is 34.91x, ROE 11.27 percent, near-zero debt at 0.02.<\/p>\n<p>For Lupin in this Cipla vs Lupin breakdown: Lupin makes Tonact (atorvastatin), Gluconorm (metformin), Suprax (cefixime) in India and complex generics in the US. P\/E is 20.29x, ROE 23.76 percent, debt to equity 0.29.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Latest_Results\"><\/span><strong>Cipla vs Lupin: Latest Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Cipla vs Lupin results for Cipla: Cipla has a market cap of Rs 1,17,138 Cr and P\/E of 34.91x. ROE is 11.27 percent with near-zero debt. Dividend yield is 0.90 percent.<\/p>\n<p>The Cipla vs Lupin results for Lupin: Lupin has a market cap of Rs 1,08,638 Cr and P\/E of 20.29x, significantly cheaper than Cipla. ROE is 23.76 percent \u2014 materially higher. Dividend yield is 0.76 percent.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Cipla and Lupin Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Stock_and_Valuation\"><\/span><strong>Cipla vs Lupin: Stock and Valuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Cipla vs Lupin stock comparison uses the latest available market data from Groww. Investors tracking Cipla vs Lupin should verify current prices on NSE or BSE before trading.<\/p>\n<p>Cipla trades at a market cap of Rs 1,17,138 Cr and P\/E of 34.91x with ROE of 11.27 percent. Lupin trades at Rs 1,08,638 Cr market cap and P\/E of 20.29x \u2014 significantly cheaper \u2014 with a much higher ROE of 23.76 percent. Lupin&#8217;s higher ROE reflects its improving US generic and India branded mix.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Quick_Comparison_Table\"><\/span><strong>Cipla vs Lupin: Quick Comparison Table<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Cipla vs Lupin comparison table below summarises the key metrics covered in this article side by side.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\">\n<tbody>\n<tr>\n<th style=\"border: 1px solid #ccc; padding: 8px;\">Parameter<\/th>\n<th style=\"border: 1px solid #ccc; padding: 8px;\"><a href=\"https:\/\/univest.in\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a><\/th>\n<th style=\"border: 1px solid #ccc; padding: 8px;\"><a href=\"https:\/\/univest.in\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a><\/th>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Sector<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Mid-large pharma: inhalers, anti-infective, US generics<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Mid-large pharma: cardiology, CNS, complex US generics<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Market Cap<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Rs 1,17,138 Cr<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Rs 1,08,638 Cr<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">P\/E Ratio<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">34.91x<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">20.29x<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">ROE<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">11.27%<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">23.76%<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Debt to Equity<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">0.02<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">0.29<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Dividend Yield<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">0.90%<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">0.76%<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Key India products<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Seroflo, Asthalin respiratory inhalers<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Tonact, Gluconorm, Suprax branded prescriptions<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">US strategy<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Inhaler biosimilars and complex generics<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Complex generics, specialty dermatology pipeline<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Cipla vs Lupin comparison above covers the key data points on reach, products, results and valuation. Cipla vs Lupin are two similarly sized mid-large pharma companies at very different valuations. Lupin is significantly cheaper with a higher ROE of 23.76 percent, while Cipla commands a premium for its inhaler franchise and US respiratory pipeline. Investors should review USFDA compliance, US pipeline approvals and India brand growth and consult a SEBI-registered advisor before investing.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest\/id1543832872\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.android\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Cipla and Lupin live price and get daily stock recommendations.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_main_difference_between_Cipla_and_Lupin\"><\/span><strong>What is the main difference between Cipla and Lupin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cipla is known for its respiratory inhaler drugs and US generic inhalers. Lupin has strong branded cardiovascular and CNS drugs in India and a complex generics and dermatology pipeline in the US.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_company_has_the_higher_ROE\"><\/span><strong>Which company has the higher ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin has an ROE of 23.76 percent, significantly higher than Cipla at 11.27 percent.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_stock_trades_at_a_lower_PE\"><\/span><strong>Which stock trades at a lower P\/E?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin trades at 20.29x trailing earnings, significantly cheaper than Cipla at 34.91x.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Ciplas_inhaler_strategy\"><\/span><strong>What is Cipla&#8217;s inhaler strategy?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cipla is developing inhaler biosimilars and complex generic inhalers including FDA-approved versions of Advair Diskus and other branded respiratory drugs for the US market.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_does_Cipla_trade_at_a_premium_to_Lupin\"><\/span><strong>Why does Cipla trade at a premium to Lupin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cipla&#8217;s respiratory inhaler franchise commands a premium as inhalers are complex drug delivery devices with higher barriers to generic entry and potentially higher margins in the US.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_apply_to_pharma_companies\"><\/span><strong>What risks apply to pharma companies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Both face risk from US FDA warning letters, generic pricing erosion, USFDA inspection observations and competition in key therapeutic segments.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_invest_in_Cipla_or_Lupin\"><\/span><strong>Should I invest in Cipla or Lupin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin is cheaper with a higher ROE. Cipla has the premium inhaler franchise. Review USFDA compliance and pipeline approvals and consult a SEBI-registered advisor before investing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cipla vs Lupin compared on India branded business, US generic pipeline, inhalation drugs and valuation. Full data-backed breakdown for pharma investors.<\/p>\n","protected":false},"author":34,"featured_media":187183,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-187184","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["187183"],"_edit_lock":["1785996527:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_title":["Cipla vs Lupin: Mid-Large Pharma Compared"],"rank_math_description":["Cipla vs Lupin compared on India branded business, US generic pipeline, inhalation drugs and valuation. Full data-backed breakdown for pharma investors."],"rank_math_focus_keyword":["Cipla vs Lupin"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_wp_old_date":["2026-08-05"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["34422"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/cipla-vs-lupin-comparison.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/187184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=187184"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/187184\/revisions"}],"predecessor-version":[{"id":188248,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/187184\/revisions\/188248"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/187183"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=187184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=187184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=187184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}